Empagliflozin

Empagliflozin is a sophisticated Active Pharmaceutical Ingredient (API) belonging to the Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor class, synthesized and manufactured at Parand Darou Co. This innovative therapeutic agent serves as a cornerstone for modern antidiabetic regimens, specifically formulated to achieve optimal glycemic control in patients with Type 2 Diabetes, while providing significant clinical benefits in reducing the risk of cardiovascular events and heart failure.

Mechanism of Action & Clinical Advantages

Empagliflozin acts through the selective inhibition of SGLT2 transporters in the renal proximal tubules, thereby effectively blocking glucose reabsorption and facilitating urinary glucose excretion (Glucosuria). This insulin-independent mechanism provides robust control of glycated hemoglobin (HbA1c) levels. Beyond glucose regulation, it offers meaningful clinical advantages, including weight reduction, management of arterial blood pressure, and=”width: 200px; background-color: #ffffff; color: #334155; font-weight: bold; padding: 12px 20px; border-radius: 10px; border: 1px solid #e2e8f0; box-shadow: 0 1px 3px rgba(0,0,0,0.05);”>Product Name
EmpagliflozinChemical Name
(2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triolManufacturer
Parand Darou Co.CAS No.
864070-44-0Category
Antidiabetic (SGLT2 Inhibitor)Pharmacopoeia
In-house

Specification